dc.contributor.author |
Mabeta, Peaceful Lucy
|
|
dc.contributor.author |
Hull, Rodney
|
|
dc.contributor.author |
Dlamini, Zodwa
|
|
dc.date.accessioned |
2023-07-19T10:48:44Z |
|
dc.date.available |
2023-07-19T10:48:44Z |
|
dc.date.issued |
2022-01-15 |
|
dc.description.abstract |
Angiogenesis is one of the hallmarks of cancer, and the establishment of new blood vessels
is vital to allow for a tumour to grow beyond 1–2 mm in size. The angiogenic switch is the term
given to the point where the number or activity of the pro-angiogenic factors exceeds that of the
anti-angiogenic factors, resulting in the angiogenic process proceeding, giving rise to new blood
vessels accompanied by increased tumour growth, metastasis, and potential drug resistance. Long
noncoding ribonucleic acids (lncRNAs) have been found to play a role in the angiogenic switch by
regulating gene expression, transcription, translation, and post translation modification. In this regard
they play both anti-angiogenic and pro-angiogenic roles. The expression levels of the pro-angiogenic
lncRNAs have been found to correlate with patient survival. These lncRNAs are also potential drug
targets for the development of therapies that will inhibit or modify tumour angiogenesis. Here we
review the roles of lncRNAs in regulating the angiogenic switch. We cover specific examples of both
pro and anti-angiogenic lncRNAs and discuss their potential use as both prognostic biomarkers and
targets for the development of future therapies. |
en_US |
dc.description.department |
Medical Oncology |
en_US |
dc.description.department |
Physiology |
en_US |
dc.description.librarian |
am2023 |
en_US |
dc.description.sponsorship |
The South African Medical Research Council (SAMRC) and the National Research Foundation (NRF). |
en_US |
dc.description.uri |
https://www.mdpi.com/journal/genes |
en_US |
dc.identifier.citation |
Mabeta, P.; Hull, R.;
Dlamini, Z. LncRNAs and the
Angiogenic Switch in Cancer:
Clinical Significance and Therapeutic
Opportunities. Genes 2022, 13, 152. https://DOI.org/10.3390/genes13010152. |
en_US |
dc.identifier.issn |
2073-4425 (online) |
|
dc.identifier.other |
10.3390/genes13010152 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/91544 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
MDPI |
en_US |
dc.rights |
© 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license. |
en_US |
dc.subject |
Vascular endothelial growth factor |
en_US |
dc.subject |
Metastasis-associated lung adeno-carcinoma transcript 1 |
en_US |
dc.subject |
HOX antisense intergenic RNA |
en_US |
dc.subject |
Maternally expressed gene3 |
en_US |
dc.subject |
MANTIS |
en_US |
dc.subject |
Myocardial infarction associated transcript |
en_US |
dc.subject |
Long noncoding ribonucleic acids (lncRNAs) |
en_US |
dc.subject |
SDG-03: Good health and well-being |
en_US |
dc.title |
LncRNAs and the angiogenic switch in cancer : clinical significance and therapeutic opportunities |
en_US |
dc.type |
Article |
en_US |